Oryzon Genomics S.A. (ORN.F)
Frankfurt · EUR · Healthcare · Biotechnology
€2.44 (+0.25%) as of
Key statistics
- Market cap
- 200.30M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 2.4440 – 3.4900
- Beta
- 0.40
- Revenue (TTM)
- 15.41M
- Profit margin
- -15.76%
- Volume
- 20.00
About Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cornellà de Llobregat, Spain
- Employees
- 46
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.